Clinical Trials · NCT00002864

Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer

Name: Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Octreotide

Phase: Phase 3
Recruitment status: Completed
Sponsor: NCIC Clinical Trials Group
Enrollment: 667
Start date: Sep 1996
Locations: 40 sites, United States, Canada
Primary endpoint: Event-free survival

View Octreotide compound reference